AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Aesthetics Portfolio by Quarter
Aesthetics Portfolio — Worldwide reported growth YoY (%) (%)
AbbVie Aesthetics Portfolio: 0.3% in Q2 2026, up 8.4 pts from a year earlier.
Latest, Q2 2026
0.3%
Period ended Jun 30, 2026
Change on a year earlier
+8.4 pts
-8.1% in Q2 2025
History
20 quarters
Since Q3 2021
Sources
20
Documents cited below
Where the Q2 2026 figure comes from
“|| Aesthetics | 761 | 521 | 1,282 | (4.4) | 8.1 | 0.3 | 5.0 | (0.9)”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie Aesthetics Portfolio (%), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta-aesth-ww-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.